Cargando…

The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis

OBJECTIVE: Juvenile idiopathic arthritis (JIA) is the most common cause of chronic arthritis in children. Biologics have changed the faith of children with rheumatic diseases. The main objective of this study was to demonstrate the rate of usage, efficacy and safety of biologics in JIA subtypes. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cakan, Mustafa, Ayaz, Nuray Aktay, Karadag, Serife Gul, Tanatar, Ayse
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kare Publishing 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117638/ https://www.ncbi.nlm.nih.gov/pubmed/32259032 http://dx.doi.org/10.14744/nci.2019.57873

Ejemplares similares

Corticosteroid-resistant anakinra-responsive protracted febrile myalgia syndrome as the first manifestation of familial Mediterranean fever
por: Cakan, Mustafa, et al.
Publicado: (2019)

Like “North Americans,” “Europeans,” or “Others:” Where do Turkish children with juvenile idiopathic arthritis stand in the new classification system?
por: Cakan, Mustafa, et al.
Publicado: (2021)

Immunodeficiency-Like Phenotype, Recurrent Pulmonary Manifestations, and Persistent Polyarthritis: Mevalonate Kinase Deficiency Successfully Treated With Adalimumab
por: ÇAKAN, Mustafa, et al.
Publicado: (2020)

Should children with psoriasis be consulted to a rheumatologist? Result from pediatric rheumatology-dermatology collaboration
por: Karadag, Serife Gul, et al.
Publicado: (2023)

Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19
por: Koker, Oya, et al.
Publicado: (2020)

Real-Life Data From the Largest Pediatric Familial Mediterranean Fever Cohort
por: Öztürk, Kübra, et al.
Publicado: (2022)

Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study
por: Cakan, Mustafa, et al.
Publicado: (2023)

How common is remission in rheumatoid factor-positive juvenile idiopathic arthritis patients? The multicenter Pediatric Rheumatology Academy (PeRA) research group experience
por: Ozdel, Semanur, et al.
Publicado: (2023)

Time to collaborate: Objectives, design, and methodology of PeRA-Research Group
por: Sozeri, Betul, et al.
Publicado: (2021)

004 Systemic autoinflammatory diseases: a multicenter cohort study
por: Tanatar, Ayşe, et al.
Publicado: (2022)

Towards a combined pediatric rheumatology-dermatology clinic: One-year experience
por: Demirkan, Fatma Gul, et al.
Publicado: (2020)

The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Demirkaya, Erkan, et al.
Publicado: (2018)

Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study
por: Otar Yener, Gülçin, et al.
Publicado: (2021)

Exploring the attitudes, concerns, and knowledge regarding COVID-19 vaccine by the parents of children with rheumatic disease: Cross-sectional online survey
por: Akgün, Özlem, et al.
Publicado: (2022)

27 Single center inception cohort of enthesitis-related arthritis: spectrum of characteristics, course and treatment approaches
por: Demirkan, Fatma Gül, et al.
Publicado: (2022)

The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
por: Alfantaki, SA, et al.
Publicado: (2011)

Anterior Segment Analysis and Evaluation of Corneal Biomechanical Properties in Children with Joint Hypermobility
por: Bayramoğlu, Sadık Etka, et al.
Publicado: (2020)

Does unity of Familial Mediterranean fever with juvenile idiopathic arthritis affect the outcome?
por: Topaloglu, R, et al.
Publicado: (2008)

Turkish Pediatric Rheumatology Society consensus statements on systemic onset juvenile idiopathic arthritis in Turkey
por: Sozeri, B, et al.
Publicado: (2015)

The Multifaceted Presentation of the Multisystem Inflammatory Syndrome in Children: Data from a Cluster Analysis
por: Sönmez, Hafize Emine, et al.
Publicado: (2022)

Efficacy and safety of Etanercept therapy in juvenile idiopathic arthritis
por: Lazareva, Arina, et al.
Publicado: (2011)

Adherence to best practice consensus guidelines for familial Mediterranean fever: a modified Delphi study among paediatric rheumatologists in Turkey
por: Kavrul Kayaalp, Gülsah, et al.
Publicado: (2021)

Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
por: Horneff, G, et al.
Publicado: (2015)

Validity and Reliability of Four Parent/Patient–Reported Outcome Measures for Juvenile Idiopathic Arthritis Remote Monitoring
por: van Dijkhuizen, E. H. Pieter, et al.
Publicado: (2022)

Juvenile idiopathic arthritis treated with biological therapies
por: Velloso Feijoo, Maria Luisa, et al.
Publicado: (2012)

Safety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis
por: Alexeeva, E, et al.
Publicado: (2011)

Efficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis
por: Nemiche, O, et al.
Publicado: (2011)

Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan
por: Imagawa, Tomoyuki, et al.
Publicado: (2012)

The use of radiosynovectomy in patients with juvenile idiopathic arthritis. Assessment of treatment efficacy and safety
por: Gazda, Agnieszka, et al.
Publicado: (2021)

Impact of biologics on growth in children with juvenile idiopathic arthritis
por: Uettwiller, F, et al.
Publicado: (2011)

Renal disorder and biological treatment in juvenile idiopathic arthritis
por: Mateescu, Lidia, et al.
Publicado: (2014)

The Biologic Basis of Clinical Heterogeneity in Juvenile Idiopathic Arthritis
por: Eng, Simon W M, et al.
Publicado: (2014)

Biomarkers of Response to Biologic Therapy in Juvenile Idiopathic Arthritis
por: Choida, Varvara, et al.
Publicado: (2021)

Persistence and adherence to biologic therapies in juvenile idiopathic arthritis
por: Nieto-González, Juan Carlos, et al.
Publicado: (2021)

Juvenile idiopathic arthritis
por: Bhatt, Krupa H, et al.
Publicado: (2014)

Juvenile Idiopathic Arthritis
por: Barut, Kenan, et al.
Publicado: (2017)

Indirect comparison of etanercept and abatacept efficacy and safety in patients with polyarticular juvenile idiopathic arthritis
por: Loskutova (Konopelko), OU, et al.
Publicado: (2014)

Efficacy of abatacept in juvenile idiopathic arthritis related uveitis
por: Katargina, LA, et al.
Publicado: (2011)

Switching to an alternative biological agent in juvenile idiopathic arthritis (I)
por: Remesal, A, et al.
Publicado: (2011)

Switching to an alternative biological agent in juvenile idiopathic arthritis (II)
por: Murias, S, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_k037l4l903sboenp1aold600am